Egypt's President Abdel Fattah El-Sisi in his meeting with Grifols CEO (Photo: Egyptian Presidency)
Egypt’s President Abdel-Fattah El-Sisi discussed on Tuesday a national project for manufacturing and collecting plasma derivatives in Cairo with the CEOs of the Spanish pharmaceutical company Grifols for the collection and manufacture of plasma derivatives, the Egyptian Presidency announced.
Prime Minister Mostafa Madbouly, Minister of Health and Population Hala Zayed, Presidential Adviser for Health and Prevention Affairs Dr. Mohamed Awad Taj El-Din, Chairman of the Unified Medical Procurement Authority Major General Dr. Bahaa El-Din Zidan, and other health officials in Egypt attended the meeting.
According to the Spokesman for the Egyptian Presidency Bassam Rady, the meeting addressed the executive general plan of the national project for the manufacture and collection of plasma derivatives in Egypt, which will be carried out in partnership with Grifols.
During the meeting, the Egyptian President directed that the implementation of the project should be expedited and the schedule be tightened, making this a huge addition to the series of national projects concerned with the health of citizens by localising the technology of manufacturing and collecting plasma in Egypt, and optimally carrying it out according to the highest international standards.
The project also aims to transfer the company's expertise with regard to the management of centers and the logistics of tracking plasma starting from the stage of collection to production, thus working efficiently in this vital field which has a direct impact on the health and safety of citizens.
El-Sisi also instructed that the plasma derivatives collection centers be established immediately in Egypt, and an effective and accurate mechanism should be set up to ensure high-quality performance in cooperation with Grifols , stressing that this project ranks high on the state’s list of priorities.
For their part, officials of the Spanish company welcomed cooperation with Egypt in the field of collecting and manufacturing plasma derivatives, transferring expertise, localising technology, and developing research centers in this field.